IRB #

STUDY00019505

Title

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer

Principal Investigator

Jeremy Cetnar

Study Purpose

The purpose of this study is to test any good and bad effects of the study drug called TAK-788. The study will also test how much it is in your blood at different times after individuals have taken TAK-788. This is the first study where TAK-788 will be tested in people.

Medical Condition(s)

non-small cell lung cancer

Eligibility Criteria

Stage IIIB-IV Non-small cell lung cancer

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Participation in the study will consist of up to 6 visits during the first month and then every 28 days for up to 3 years. Visits will last up to 8-9 hours. Follow up through the use of medical record review or follow up phone calls will last for up to 3 years from when the last subject is enrolled.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Recruitment End

01/01/2025

Compensation Provided

No


Go Back